Recent Updates
Recently added Catalysts
SNDA Positive Sentiment

Sonida Senior Living Announces Second Quarter Earnings Release Date and Conference Call

Monday, August 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Sonida Senior Living, Inc. announced its second quarter 2026 earnings release date, set for August 10, 2026, before market opening. Following the release, the company will host a conference call at 11:00 a.m. Eastern Time to discuss its financial performance and operating results. This event reflects Sonida's commitment to keeping stakeholders informed.
Price reaction · baseline $40.36 (2026-07-31 close) · hit pre-market · clean, no other SNDA news in the window
day 0 close
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sonida Senior Living is preparing to release its second quarter earnings.
  • The company is actively engaging with investors through a conference call.
  • The scheduled earnings release indicates a commitment to transparency.

Full Press Release Details

DALLAS--(BUSINESS WIRE)--Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in communities and services for seniors, announced today that it will issue its second quarter 2026 earnings results before the market opens for trading on Monday, August 10, 2026. The Company will then host a conference call and webcast to review its financial performance and operating results at 11:00 a.m. Eastern Time. The dial-in number for the conference call

Frequently Asked Questions

When will Sonida release its Q2 earnings?

Sonida will release its Q2 2026 earnings on August 10, 2026.

What time is the conference call for Q2 earnings?

The conference call will be held at 11:00 a.m. Eastern Time.

How can I join the Sonida earnings conference call?

Details for joining the conference call will be provided during the earnings release.

ShareAdd on Google
Tags: SNDA Sonida Senior Living earnings release conference call financial performance
Last updated: Aug 3, 2026

Biotech snapshot

Cash runway
$49M liquidity · $0M/mo burn
Low dilution risk